Hsia, Oliver
Hinterndorfer, Matthias http://orcid.org/0000-0003-2435-4690
Cowan, Angus D. http://orcid.org/0000-0002-9702-7319
Iso, Kentaro http://orcid.org/0000-0001-5417-3642
Ishida, Tasuku http://orcid.org/0000-0001-7592-7925
Sundaramoorthy, Ramasubramanian
Nakasone, Mark A. http://orcid.org/0000-0002-1362-191X
Imrichova, Hana http://orcid.org/0000-0003-0385-1823
Schätz, Caroline
Rukavina, Andrea http://orcid.org/0000-0001-8254-9360
Husnjak, Koraljka http://orcid.org/0000-0003-0573-6239
Wegner, Martin http://orcid.org/0000-0001-6403-3926
Correa-Sáez, Alejandro http://orcid.org/0000-0001-5240-4865
Craigon, Conner
Casement, Ryan
Maniaci, Chiara
Testa, Andrea http://orcid.org/0000-0002-8973-9711
Kaulich, Manuel http://orcid.org/0000-0002-9528-8822
Dikic, Ivan http://orcid.org/0000-0001-8156-9511
Winter, Georg E. http://orcid.org/0000-0001-6606-1437
Ciulli, Alessio http://orcid.org/0000-0002-8654-1670
Article History
Received: 18 February 2023
Accepted: 18 January 2024
First Online: 21 February 2024
Competing interests
: A.C. is a scientific founder, shareholder and advisor of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KaaG, Nurix Therapeutics, Ono Pharmaceutical and Tocris-Biotechne. A.T. is currently an employee of Amphista Therapeutics. G.E.W. is scientific founder and shareholder of Proxygen and Solgate. The Winter laboratory has received research funding from Pfizer. The other authors declare no competing interests.